Which parameter would be the least appropriate to monitor in a patient recently started on atorvastatin and lisinopril who has no symptoms?

Which parameter would be the least appropriate to monitor in a patient recently started on atorvastatin and lisinopril who has no symptoms?

• A. Creatine kinase
• B. Liver enzymes
• C. Creatinine
• D. Blood pressure

Answer: (D)

When a patient is started on a statin and an ACE inhibitor but has no symptoms, monitoring focuses on potential adverse effects specific to each drug and on how the body responds to the therapies. For a statin like atorvastatin, the main concern is liver safety. Baseline liver enzymes are often checked because rare hepatotoxicity can occur, and clinicians may repeat them if symptoms of liver injury appear. Creatine kinase is not routinely monitored in an asymptomatic patient on a statin; it’s reserved for when muscle symptoms such as pain, weakness, or dark urine develop, suggesting possible statin-induced myopathy. For an ACE inhibitor like lisinopril, monitoring targets kidney function and blood pressure, since this class can affect renal function and electrolyte balance, and it lowers blood pressure. So creatinine (to assess kidney function), potassium, and blood pressure readings are all appropriate and useful after starting therapy. Therefore, among these options, the parameter that is least appropriate to monitor routinely in an asymptomatic patient is creatine kinase.

When a patient is started on a statin and an ACE inhibitor but has no symptoms, monitoring focuses on potential adverse effects specific to each drug and on how the body responds to the therapies. For a statin like atorvastatin, the main concern is liver safety. Baseline liver enzymes are often checked because rare hepatotoxicity can occur, and clinicians may repeat them if symptoms of liver injury appear. Creatine kinase is not routinely monitored in an asymptomatic patient on a statin; it’s reserved for when muscle symptoms such as pain, weakness, or dark urine develop, suggesting possible statin-induced myopathy.

For an ACE inhibitor like lisinopril, monitoring targets kidney function and blood pressure, since this class can affect renal function and electrolyte balance, and it lowers blood pressure. So creatinine (to assess kidney function), potassium, and blood pressure readings are all appropriate and useful after starting therapy.

Therefore, among these options, the parameter that is least appropriate to monitor routinely in an asymptomatic patient is creatine kinase.